Diagnosing and Treating Low Blood Sugar Levels
Study Details
Study Description
Brief Summary
Hypoglycemia is the term used to refer to lower than normal levels of blood sugar. This study will continue to research the causes of hypoglycemia.
Patients involved in the study will be admitted to the Clinical Center of the National Institutes of Health and undergo tests for evaluating blood sugar. Patients will be required to refrain from eating for a set period of time and will undergo blood tests for insulin levels and several other specific diagnostic tests related to insulin secretion. The patients will be under supervision and will be provided with appropriate medical and surgical attention as needed.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
|
Detailed Description
The purpose of this protocol is to continue our studies of the evaluation and treatment of patients with fasting hypoglycemia due to diverse etiologies. Patients will be admitted to the Clinical Research Center under this protocol and undergo supervised fasting, dynamic tests of insulin secretion when appropriate, medically indicated imaging studies, and appropriate medical and surgical treatment.
The goals of this study are:
-
To understand the pathophysiology and various causes of hypoglycemia (e.g.,insulinomas, MEN1, MEN2).
-
To identify new circulating biomarkers of insulinomas.
-
To create a repository of clinical data and samples for future research of insulinomas.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Patients with hypoglycemia Patients with hypoglycemia due to diverse etiologies. |
Outcome Measures
Primary Outcome Measures
- Treatment Outcomes [every 1-3 months]
resolution of hypoglycemia
Eligibility Criteria
Criteria
- INCLUSION CRITERIA:
In order to be eligible to participate in this study, an individual must meet all of the following criteria:
-
Male, females ages >= 18.
-
Patients with documented fasting blood glucose below 55 mg/dl.
-
Patients with biochemical evidence for insulinoma or other neuroendocrine tumors.
EXCLUSION CRITERIA:
An individual who meets any of the following criteria will be excluded from participation in this study:
-
Patients with known sulfa allergies and patients with significant cardiac disease will be excluded.
-
Subjects who are pregnant.
-
Medically unstable per the assessment of the PI.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | National Institutes of Health Clinical Center, 9000 Rockville Pike | Bethesda | Maryland | United States | 20892 |
Sponsors and Collaborators
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Investigators
- Principal Investigator: Ranganath Muniyappa, M.D., National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Study Documents (Full-Text)
None provided.More Information
Additional Information:
Publications
- Bar RS, Gorden P, Roth J, Siebert CW. Insulin receptors in patients with insulinomas: changes in receptor affinity and concentration. J Clin Endocrinol Metab. 1977 Jun;44(6):1210-3.
- Blackshear PJ, Rotner HE, Kriauciunas KA, Kahn CR. Reactive hypoglycemia and insulin autoantibodies in drug-induced lupus erythematosus. Ann Intern Med. 1983 Aug;99(2):182-4.
- Comi RJ, Gorden P. Approach to hypoglycemia in adults. Compr Ther. 1987 Mar;13(3):38-44.
- 910066
- 91-DK-0066